Navigation Links
Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. The article in the April 24 edition of JACC concluded that the shorter procedure time and lower bailout rate of the TAXUS Liberte Stent system compared to the TAXUS(R) Express2(TM) Stent system may represent a clinical surrogate for the improved deliverability and conformability of the TAXUS Liberte Stent as compared to the TAXUS Express Stent.

TAXUS ATLAS is a global, multi-center single arm trial comparing the TAXUS Liberte paclitaxel-eluting stent system to a case-matched control group of patients from the TAXUS IV and TAXUS V de novo studies that received the TAXUS Express2 paclitaxel-eluting stent system. Even with more complex lesion characteristics(2) compared to the control group, the TAXUS ATLAS trial met its primary endpoint of nine-month target vessel revascularization (TVR) non-inferiority.

The TAXUS ATLAS nine-month results also support safety, as demonstrated by low rates of Major Adverse Cardiac Events (MACE) and stent thrombosis. The MACE rate and its components, including cardiac death, myocardial infarction and TVR, were comparable to control despite the higher percentage of complex lesions for the TAXUS Liberte Stent arm. Cardiac death for the control group was 0.9 percent compared to 0.8 percent for the TAXUS Liberte Stent (p=1.00). Myocardial infarction was 3.9 percent for the control group compared to 3.7 percent for the TAXUS Liberte Stent (p=0.9030). The nine-month TVR rate for the control group was 7.1 percent compared to 8.0 percent for the TAXUS Liberte Stent (p=0.4787). Similar TVR rates of 9.2 percent for the TAXUS Liberte Stent group, as compared to 8.9 perc
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
(Date:7/21/2014)... -- An International Trade Commission (ITC) ruling issued Friday held ... Taiwanese device manufacturer APEX continues to infringe ResMed patents ... is the innovation leader and pioneer in designing and ... "Our research and development teams are constantly ... comfort, performance and efficacy," said David Pendarvis , ...
(Date:7/21/2014)... July 21, 2014 Apex Medical Corporation (Apex, ... and Pressure Area Care sectors, announces that the United ... advisory opinion, determining that Apex,s newly designed XT series ... 220 mask are free from the patent claims asserted ... declares its plan of introducing an upgraded iCH water ...
(Date:7/18/2014)... Hanger, Inc. (NYSE: HGR ) announced today that ... quarter ended June 30, 2014, on Tuesday, August 5, 2014 ... results is scheduled to begin at 9:00 a.m., ET, on ... 1-877-662-6095. A replay will be available until Thursday, August 14, ... About Hanger, Inc. – Built on the legacy ...
Breaking Medicine Technology:ITC Rules Redesigned APEX Humidifier Still Infringes ResMed Patents 2Apex Medical's Respiratory Therapy Product Receives Affirmation from USITC 2
(Date:7/21/2014)... July 21, 2014 What do romance, ... have in common? You can find them all in ... novel's main character, Miranda, lives on Martha’s Vineyard with ... a wealthy New Yorker, and becomes entangled in a ... Heart challenges readers to think about what choices they ...
(Date:7/21/2014)... (Philadelphia, PA) Patients who have a clot ... be treated with traditional blood-thinning medication or undergo ... comfortable that there is no difference in death ... more bleeding risks with the catheter procedure, according ... Medicine researchers. The study involved a review of ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 Executives ... agency specializing in private healthcare practices, will participate ... (IACA). They will be showcasing their state-of-the-art capabilities ... medical practices all over the United States as ... efforts continues to increase. Advice Media’s presence at ...
(Date:7/21/2014)... MONDAY, July 21, 2014 (HealthDay News) -- The "viral ... avoiding detection and elimination, is established much earlier than ... poses new obstacles for those working to eradicate the ... Military HIV Research Program. They said the presence of ... finding a cure for a subtype of HIV, known ...
(Date:7/21/2014)... Public Affairs Research has released the results of a ... means to be a quality health care provider in ... Wood Johnson Foundation, sheds new light on how American ... doctors, as well as the information they use and ... new and actionable data during a crucial period of ...
Breaking Medicine News(10 mins):Health News:Thea Marsh Releases Debut Novel that Celebrates and Reaches out to Women Everywhere 2Health News:Temple study compares deep vein thrombosis therapies 2Health News:Temple study compares deep vein thrombosis therapies 3Health News:Temple study compares deep vein thrombosis therapies 4Health News:Advice Media to Attend the International Association of Comprehensive Aesthetics Conference (IACA) Targeting the Dental Profession 2Health News:Animal Experiments Shed Light on HIV's Ability to Hide 2Health News:National survey from AP-NORC examines perceptions of health care provider quality 2
... Central government and striking medicos to end the agitation ... Castes// in educational institutes failed to reach any conclusion ... decision to implement the 27% reservation for OBCs in ... that they would plan to make their agitation 'more ...
... to a study it was found that a number ... measures, like a daily dose of aspirin, colon cancer ... young women, immunizing adults against the flu and pneumonia ... longer and healthier lives. The study’s results were published ...
... Ranbaxy Laboratories Limited today entered into an in-licensing agreement ... (NDDS) analgesic // , Tramadol in the Indian market ... the wholly-owned subsidiary of the French drug major for ... ,The product will be supplied from Ethypharm's manufacturing ...
... Laboratories Limited today said the World Health Organistion has ... products in its pre-qualification list. // ,The ... 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, the ... significant development. We strongly feel that Generic ARVs are ...
... aroused as fear about childhood obesity grows and thus ... ... child-sized machines, during the past two years. ... Shokk and Zig Zag was building new facilities and installing machines for their little customers. ,According to ...
... Cabinet today cleared the business model for the state-of-the-art Institute ... the capital. // ,The model approved by the ... would enable the institute to be self-sufficient in nine years' ... the finances for procuring medical equipment would be borne by ...
Cached Medicine News:Health News:Disappointed Students Plan To Intensify Agitation Nationwide 2
... The SJM Tailor Flexible Band ... a convenient and time-saving alternative for ... It complements the SJM Tailor® Annuloplasty ... who usually implant full rings, but ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,407-0) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
Medicine Products: